Recombinant antigenized secretory IgA recovered for use as vaccine vector.

2003 MAY 7 - (NewsRx.com & NewsRx.net) -- Researchers have developed a simplified procedure to recover recombinant antigenized secretory IgA for use as a vaccine vector.

"Induced protection mechanisms at mucosal surfaces involve secretory IgA (SIgA), a complex structure made of polymeric-dimeric IgA (IgAp[subscript]p/d) antibody associated with secretory component (SC). SIgA can adhere to M cells of the intestinal and nasal epithelia, are transported across these latter, and are thus available to the immune cells underlying the epithelia. This property makes SIgA suitable as potential mucosal vaccine delivery vector," investigators in Switzerland report.

"It remains that production and purification of SIgA is a complex task since IgAp[subscript]p/d and SC are naturally synthesized by two different cell types," commented Laurent I. Favre and colleagues at Centre Hospitalier Universitaire Vaudois in Lausanne. "Furthermore, only IgAp[subscript]p/d are capable to associate with SC. Thus, we sought to separate IgAp[subscript]p/d and monomeric IgA (IgA[subscript]m) antibodies secreted by hybridoma cells in CELLine bioreactors. To this aim, we connected together two 1-meter long columns filled with Sephacryl S-300 beads and placed them under the control of a automatized chromatographic system.

"In parallel, we produced recombinant antigenized human SC (ra-hSC) in Chinese hamster ovary (CHO) cells adapted to suspension culture in CELLine bioreactors. To avoid intermediate purification of ra-hSC, culture supernatants (SN) ...